by April Breyer Menon | Feb 18, 2022
Venable’s Ha Kung Wong and April Breyer Menon delve into the practical implications of the US Supreme Court’s ruling in U.S. v. Arthrex, including the outcomes of requests for director review, time to decision on the requests, and potential future issues with...
by April Breyer Menon | Nov 30, 2021
On November 16, 2021, Viatris and Biocon announced the launch of two interchangeable insulin glargine products, a branded version, Semglee® (insulin glargine-yfgn) injection, and an unbranded version, Insulin Glargine (insulin glargine-yfgn) injection, both of which...
by April Breyer Menon | Nov 10, 2021
Download PDF Download...
by April Breyer Menon | Oct 25, 2021
On October 15, 2021, the FDA approved Boehringer Ingelheim’s Cyltezo® (adalimumab-adbm) as interchangeable with AbbVie’s Humira® (adalimumab) for many of Humira’s approved indications. As an interchangeable, Cyltezo can be automatically substituted for Humira...
by April Breyer Menon | Oct 22, 2021
Ha Kung Wong, Wei Campbell, and Christine Cochran gave a LSPN Live presentation titled “US Patent Legal Landscape Outlook: What are the Main Challenges Facing the US Patent System and how do we Prepare for them?” where they discussed recent Supreme...